Singapore markets close in 2 hours 40 minutes

Straits Times Index
3,144.41
-39.20(-1.23%)
Nikkei
38,471.20
-761.60(-1.94%)
Hang Seng
16,288.43
-312.03(-1.88%)
FTSE 100
7,965.53
-30.05(-0.38%)
Bitcoin USD
62,881.74
-3,224.15(-4.88%)
CMC Crypto 200
885.54
0.00(0.00%)

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD

Add to watchlist

161.67

-0.61

(-0.38%)

At close: 04:00PM EDT

161.05

-0.62

(-0.38%)

After hours:

07:55PM EDT

Trade prices are not sourced from all markets

All

Benzinga
What's Going On AbbVie Stock On Friday?
Friday, AbbVie Inc (NYSE:ABBV) released an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The shares are trading lower with a session volume of 3.9 million versus the average volume of 5.6 million, as per the data from Benzinga Pro. Also Read: AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue an
PR Newswire
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcome
Zacks
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.